Indoco Remedies · NSE: INDOCO · BSE: 532612
Q3 FY21 results · Oct–Dec 2020
Indoco Remedies reported revenue from operations of ₹332.29 crore (up 14.8% from Q3 FY20) and net profit of ₹25.36 crore (up 178.7% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a consolidated basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 332.29 | 289.35 | +14.8% | 328.24 | +1.2% |
| Other income | 0.36 | 0.72 | −50.0% | 0.52 | −30.8% |
| Total income | 332.65 | 290.07 | +14.7% | 328.76 | +1.2% |
| Profit before tax | 37.63 | 11.07 | +239.9% | 36.78 | +2.3% |
| Net profit for the period | 25.36 | 9.10 | +178.7% | 25.65 | −1.1% |
| EPS, basic (₹) | 2.75 | 0.99 | +177.8% | 2.78 | −1.1% |
| Net margin (%) | 7.6 | 3.1 | 7.8 |
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 331.94 | 289.34 | +14.7% | 327.65 | +1.3% |
| Other income | 0.37 | 0.72 | −48.6% | 0.52 | −28.8% |
| Total income | 332.31 | 290.06 | +14.6% | 328.17 | +1.3% |
| Profit before tax | 37.42 | 11.32 | +230.6% | 36.24 | +3.3% |
| Net profit for the period | 25.14 | 9.34 | +169.2% | 25.11 | +0.1% |
| EPS, basic (₹) | 2.73 | 1.01 | +170.3% | 2.72 | +0.4% |
| Net margin (%) | 7.6 | 3.2 | 7.7 |
Consolidated
- Filed with BSE
- 09 Feb 2021, 14:10 IST
- Board meeting
- 09 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 Feb 2021, 14:10 IST
- Board meeting
- 09 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE